Management credits this growth to a two-pronged strategy involving a recovery in Canadian retail and rapid scaling in Germany. The company’s bricks-and-mortar segment saw same-store sales return to positive year-over-year growth in June and July, defying broader market trends. Simultaneously, its German subsidiary, Remexian Pharma GmbH, achieved a distribution record of over 10 tonnes of medical cannabis flower, marking a 60% increase compared to the previous year.
Founder and CEO Raj Grover stated that the firm’s performance exceeds the high end of current analyst estimates, suggesting that market expectations have not yet fully accounted for the company's operating leverage. High Tide plans to disclose its full financial and operational results on September 14, 2026, followed by a conference call the next morning to detail the quarter's outcomes.
Comments (0)
No comments yet. Be the first!